FDA Clears Immunotherapy Add-On for Stage III Colon Cancer With Specific DNA Repair Flaw

The Food and Drug Administration on October 8 approved a new post-surgery treatment regimen for adults and some pediatric patients with stage III colon cancer that carries a deficiency in DNA mismatch repair, a molecular marker that affects how a tumor responds to the immune system.

The approval covers atezolizumab (Tecentriq), a PD-L1 immune checkpoint inhibitor made by Roche's Genentech, given alongside a fluoropyrimidine-and-oxaliplatin chemotherapy backbone. According to a statement reviewed by the Mayo Clinic News Network, this is the first adjuvant immunotherapy regimen the FDA has cleared for this patient population.

The decision rests on the phase 3 ATOMIC trial, a multicenter, randomized study. As reported by ONC Nursing News, the trial enrolled 712 patients whose tumors were dMMR and had been surgically removed, with spread to regional lymph nodes but no evidence of distant metastasis. Patients got standard chemotherapy alone or chemotherapy paired with atezolizumab, followed by additional atezolizumab. The primary endpoint was disease-free survival.

The numbers are notable. According to the Mayo Clinic News Network, at three years, 86.3% of patients in the combination arm were alive and disease-free, compared with 76.2% in the chemotherapy-alone arm. That translates to a 50% reduction in the hazard of recurrence or death. The findings were published in The New England Journal of Medicine.

The patient population here matters, and it's worth being precise about who this actually reaches. Not all stage III colon cancers carry the dMMR marker. The trial enrolled patients specifically selected for that tumor biology, and the approval is written to match. Oncologists will need to confirm dMMR status before this regimen applies.

Frank Sinicrope, a Mayo Clinic oncologist who led the ATOMIC study, told the Mayo Clinic News Network that until this approval, adjuvant treatment for stage III colon cancer did not differ based on mismatch repair status. That's a meaningful clinical gap this fills.

The European Pharmaceutical Review noted that the approval extends to a subcutaneous formulation, atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza), for patients 12 and older who weigh at least 40 kilograms, which could matter for patients who have difficulty tolerating intravenous infusions.

The ONC Nursing News report flagged that the combination came with more grade 3 to 4 adverse events than chemotherapy alone, a detail that will matter to oncologists when they sit down with patients to talk through the tradeoff. The trial reported the benefit in disease-free survival, but the toxicity profile is part of the conversation, not a footnote.

Colorectal cancer is the second leading cause of cancer death in the United States. According to the Colorectal Cancer Alliance, as cited in ONC Nursing News, one in three patients with stage III colon cancer will relapse within five years. That context is what makes an adjuvant therapy aimed at cure, rather than at advanced disease, worth paying attention to.

For patients with this specific tumor type who've just come through surgery, the question shifts from whether an option exists to whether they and their oncologist decide the benefit-to-risk ratio holds. That's a conversation that will now happen in clinics instead of in trial enrollment offices.

Sources cited:
- Mayo Clinic News Network (https://newsnetwork.mayoclinic.org/discussion/fda-approves-immunotherapy-regimen-studied-by-mayo-clinic-for-stage-3-colon-cancer/)
- ONC Nursing News (https://www.oncnursingnews.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-3-dmmr-colon-cancer)
- European Pharmaceutical Review (https://www.europeanpharmaceuticalreview.com/fda-approves-roches-tecentriq-immunotherapy-combination-for-dmmr-colon-cancer/2136715.article)
- OncoDaily (https://oncodaily.com/gastrointestinal-oncology/fda-approval-atomic)